CNX Resources Corp. will announce its financial results for the third quarter of 2026 on October 29 at 6:45 a.m. ET. The company will release a press statement with prepared remarks, presentation materials, and supplemental updates on its Investor Relations website. Following the release, CNX will host a Q&A conference call and webcast at 10:00 a.m. ET for investors to discuss the results. CNX is a natural gas company focused on low carbon operations in Appalachia, holding significant proved reserves and aiming to create long-term shareholder value.
CNX Resources Corporation's upcoming Q3 2026 financial results announcement provides context for energy sector investors. For readers following the energy sector, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: Of 38 priced US energy stocks, 29 rose and 9 fell today. Notable movers include Tidewater Inc (TDW) at USD 84.38 with a 1-day change of +2.37% and a typical hold time on Pluang of 25 days, Cenovus Energy Inc (CVE) at USD 32.39 with a 1-day change of +2.34% and Pluang order activity showing 0% Sell / 100% Buy, and Phillips 66 (PSX) at USD 270.00 with a 1-day change of +2.05% and a typical hold time on Pluang of 62 days.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
